Resource library search

Following the FDA approval of Immunocore's treatment of metastatic uveal melanoma (mUM), KIMMTRAK, guest author Sir John Bell shares what this could mean for the UK life sciences.

Ahead of BioBeat24, Iraida Soria-Espinosa, Senior Innovation & Business Manager at UK DRI, and Miranda Weston-Smith, Founder of BioBeat, caught up with keynote speaker Zoe Kourtzi, Professor of Computational Cognitive Neuroscience at the University of Cambridge.

Correct as of 15 September 2021. This is a briefing for BIA members on the Government led by Boris Johnson, and key ministerial appointments following the most recent reshuffle.

A highlight of the life sciences calendar and celebrating the achievements of the life science sector, the sold out 2021 Bionow Awards showcased the very best of this world class field.

Dr Mark Kotter, CEO and Founder of bit.bio, stem cell biologist and complex spine neurosurgeon, speaks about the company and the importance of SynBio as part of the UK Life Sciences Vision.

On the 17 September 2019, the BIA will be hosting its Regulatory Innovation Conference at 30 Euston Square. The conference will explore the UK’s global capability for clinical trials, how we bring innovative medicines to market, evidence generation in support of regulatory decision-making and looking to the future, and what will the role of the regulator be as part of the global innovation ecosystem?

Fletch Fletcher, Vice President of Marketing at Lifebit, shares his journey since joining the life sciences sector, and his fascination on how the sector is impacting humanity.

A statement regarding Kate Bingham and the Vaccine Taskforce

Ian McCubbin is the former Vaccine Manufacturing lead on the Vaccine Taskforce and former chair of the BIA COVID-19 Vaccine Manufacturing Taskforce. Ian is also a BIA board member. Ian has written about his investiture ceremony and passes along an important message from the royal family to the many individuals and companies involved in supporting various vaccine candidates.

In this blog, Kelsey Lawrence, the Senior Corporate Partnerships Officer for Bowel Cancer UK, reflects on the highlights of the collaboration; the BIA Gala Dinner which kickstarted the partnership, raising over £30,000, the '5 Biotech Wonders of the World' challenge, and the overall success achieved through the BIA partnership,

London, UK, 16th September 2021 – A 6-month collaborative project was announced today that will help to accelerate the introduction of regulated advanced gene therapies that use Adenovirus-associated vectors (AAVs).